BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res 2011;35:526-33. [PMID: 20951430 DOI: 10.1016/j.leukres.2010.09.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Salomè M, Campos J, Keeshan K. TRIB2 and the ubiquitin proteasome system in cancer. Biochem Soc Trans 2015;43:1089-94. [PMID: 26517929 DOI: 10.1042/BST20150103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
2 Hynes-Smith RW, Swenson SA, Vahle H, Wittorf KJ, Caplan M, Amador C, Hyde RK, Buckley SM. Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. Cancers (Basel) 2019;11:E1717. [PMID: 31684170 DOI: 10.3390/cancers11111717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Gorodkiewicz E, Ostrowska H, Sankiewicz A. SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma. Mikrochim Acta 2011;175:177-84. [PMID: 21966027 DOI: 10.1007/s00604-011-0656-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
4 Hempel D, Wojtukiewicz MZ, Kozłowski L, Romatowski J, Ostrowska H. Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. Tumour Biol 2011;32:753-9. [PMID: 21611786 DOI: 10.1007/s13277-011-0177-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Csizmar CM, Kim DH, Sachs Z. The role of the proteasome in AML. Blood Cancer J 2016;6:e503. [PMID: 27911437 DOI: 10.1038/bcj.2016.112] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
6 Dos Santos C, McDonald T, Ho YW, Liu H, Lin A, Forman SJ, Kuo YH, Bhatia R. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 2013;122:1900-1913. [PMID: 23896410 DOI: 10.1182/blood-2012-11-466425] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
7 Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, Gonzalez-toledo E, Albitar M. Plasma ubiquitin–proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b. Neurological Research 2013;34:611-8. [DOI: 10.1179/1743132812y.0000000055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
8 Pascovici D, Wu JX, McKay MJ, Joseph C, Noor Z, Kamath K, Wu Y, Ranganathan S, Gupta V, Mirzaei M. Clinically Relevant Post-Translational Modification Analyses-Maturing Workflows and Bioinformatics Tools. Int J Mol Sci 2018;20:E16. [PMID: 30577541 DOI: 10.3390/ijms20010016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]